GlassScriptPhysician profile
Raquel Joye Lins
NPI 1063199131
$922.44
in general payments reported to CMS, 2019-2025
20 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $615 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $183.94 | 2023-2025 | |
| Pfizer INC. | $142.24 | 2024 | |
| Exact Sciences Corporation | $72.72 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $62.85 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $51.37 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $49.02 | 2024-2025 | Korlym |
| Corium, LLC | $42.64 | 2023-2024 | Azstarys |
| Lundbeck LLC | $40.63 | 2023 | Rexulti |
| Amgen INC. | $33.14 | 2024 | Krystexxa |
| Coopersurgical, INC. | $27.51 | 2025 | Paragard T 380a |
| Boston Scientific Corporation | $26.64 | 2024 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $26.00 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $25.27 | 2024-2025 | Voquezna |
| Acadia Pharmaceuticals INC | $22.96 | 2024 | Daybue |
| Neurocrine Biosciences, INC. | $22.01 | 2024 | Ingrezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.03 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.27 | 2023 | Xifaxan, Trulance |
| Dexcom, INC. | $19.07 | 2025 | Dexcom G6 Transmitter |
| Neurelis, INC. | $18.79 | 2024 | Valtoco |
| Janssen Pharmaceuticals, INC | $14.34 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Lins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.